Tag: Sandoz
Generics subsidiary – Novartis separates from Sandoz – News
The Basel pharmaceutical company Novartis separates from Sandoz. The generics manufacturer is to become an independent company. The company’s headquarters will remain in Switzerland. According to Novartis, the transaction should…
Novartis spins off Sandoz
Last fall, Novartis announced that it would examine “all options” for Sandoz. Now the generics division is to be listed as an independent company on the Swiss stock exchange. The…
Novartis feels the firm dollar, Sandoz will probably be split off
The strengthening of the dollar is a burden for the drug manufacturer Novartis. The loss of the stake in Roche has had a negative impact on the group result. The…
Novartis: Sandoz acquires inhaler specialist Coalesce
Zurich (awp) – The pharmaceutical firm Sandoz, a subsidiary of Novartis, has acquired the British company Coalesce, a specialist in inhalation devices. The transaction amount was not sent. The generics…
Big moves in sight on Sandoz this year at Novartis
Subscribe for 1€ Unlimited access to all advice More than 800 stocks listed in Paris and abroad screened. To buy ? To sell ? What course objective? Our experts engage…
Novartis aims for growth in 2022, no decision yet on Sandoz
(Updated with details, background, quotes and stock quotes) FRANKFURT, Feb 2 (Reuters) – Novartis said on Wednesday it expects revenue and operating profit growth of around 5% this year as…
Novartis: application for approval of Sandoz for trastuzumab with the EMA
Zurich (awp) – Sandoz takes a further step towards the commercialization of the biosimilar trastuzumab in the European Union. The Novartis subsidiary has filed an application for marketing authorization for…
Novartis: Sandoz wants to launch a generic of Herceptin
(CercleFinance.com) – Sandoz, the generic drug subsidiary of Novartis, announced on Tuesday that it had submitted a biologics license application (BLA) to the Food and Drug Administration (FDA) for a…
Corona and price pressure: Novartis is examining the future of the generics subsidiary Sandoz
Tuesday, October 26, 2021 Corona and price pressure Novartis is examining the future of the generics subsidiary Sandoz It generates every fifth euro – but generates comparatively little income: The…